Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.

Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives

Open access
Kim, Hyeong Min, Woo, Se Joon · 2021 · Pharmaceutics

Abstract

Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growth factor intravitreal injection methods. However, because intravitreal treatment requires monthly or bimonthly repeat injections to achieve optimal efficacy, recent investigations have focused on extended drug delivery systems to lengthen the treatment intervals in the long term. Dose escalation and increasing molecular weight of drugs, intravitreal implants and nanoparticles, hydrogels, combined systems, and port delivery systems are presently under preclinical and clinical investigations. In addition, less invasive techniques rather than intravitreal administration routes, such as topical, subconjunctival, suprachoroidal, subretinal, and trans-scleral, have been evaluated to reduce the treatment burden. Despite the latest advancements in the field of ophthalmic pharmacology, enhancing drug efficacy with high ocular bioavailability while avoiding systemic and local adverse effects is quite challenging. Consequently, despite the performance of numerous in vitro studies, only a few techniques have translated to clinical trials. This review discusses the recent developments in ocular drug delivery to the retina, the pharmacokinetics of intravitreal drugs, efforts to extend drug efficacy in the intraocular space, minimally invasive techniques for drug delivery to the retina, and future perspectives in this field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics13010108

Cites

200 of 200 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic of several ocular drug administration routes: (1) topical route, (2) subconjunctival route, (3) suprachoroidal route with microcannula and microneedle, (4) subretinal route, and (5) intravitreal injection and port delivery system.
Figure 1 Schematic of several ocular drug administration routes: (1) topical route, (2) subconjunctival route, (3) suprachoroidal route with microcannula and microneedle, (4) subretinal route, and (5) intravitreal injection and port delivery system.CC BY · PubMed Central
Figure 2 Schematic depicting the latest advancement in multiple ocular drug delivery systems: (1) Antibody+Biopolymer conjugate, (2) Biodegradable intravitreal implant, (3) Non-biodegradable intravitreal implant, (4) Triamcinolone acetonide microparticles, (5) Dendrimer, (6) Liposome, (7) Micelle, (8) Polymeric nanoparticles, (9) Hydrogel, (10) Hydrogel implant, (11) Combined systems, and (12) Viral vector.
Figure 2 Schematic depicting the latest advancement in multiple ocular drug delivery systems: (1) Antibody+Biopolymer conjugate, (2) Biodegradable intravitreal implant, (3) Non-biodegradable intravitreal implant, (4) Triamcinolone acetonide microparticles, (5) Dendrimer, (6) Liposome, (7) Micelle, (8) Polymeric nanoparticles, (9) Hydrogel, (10) Hydrogel implant, (11) Combined systems, and (12) Viral vector.CC BY · PubMed Central
Figure 3 Schematic displaying intraocular distribution and elimination pathways of standard anti-VEGF intravitreal treatment and other drug administration routes. After intravitreal injection, small protein anti-VEGF antibodies move toward the anterior and posterior segment of the eye and are cleared by both pathways. Topical agents are mainly distributed in the anterior segment due to multiple physical barriers, such as the cornea and conjunctiva; however, recent drugs have utilized trans-scleral diffusion to the target posterior segment. Subconjunctival agents could also reach the posterior segment via trans-scleral diffusion of the particles. Because drug agents can move directly into the posterior segment via the suprachoroidal space, the suprachoroidal routes, via microcannula and microneedle, are promising. Subretinal injection into the subretinal space could also be employed to directly target the retinal layer.
Figure 3 Schematic displaying intraocular distribution and elimination pathways of standard anti-VEGF intravitreal treatment and other drug administration routes. After intravitreal injection, small protein anti-VEGF antibodies move toward the anterior and posterior segment of the eye and are cleared by both pathways. Topical agents are mainly distributed in the anterior segment due to multiple physical barriers, such as the cornea and conjunctiva; however, recent drugs have utilized trans-scleral diffusion to the target posterior segment. Subconjunctival agents could also reach the posterior segment via trans-scleral diffusion of the particles. Because drug agents can move directly into the posterior segment via the suprachoroidal space, the suprachoroidal routes, via microcannula and microneedle, are promising. Subretinal injection into the subretinal space could also be employed to directly target the retinal layer.CC BY · PubMed Central
Figure 4 Summary of current development and human clinical trials for enhanced ocular drug delivery to the posterior segment of the eye.
Figure 4 Summary of current development and human clinical trials for enhanced ocular drug delivery to the posterior segment of the eye.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 200 references

Cited by

See all 213

Metadata

Authors
Kim, H. M., & Woo, S. J.
Affiliations
Seoul National University (KR)
Corresponding author
Woo, Se Joon
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2021-01-15
Volume
13
Issue
1
Pages
108
ISSN
1999-4923 (ISSN-L)
OpenAlex
W3118619250
Cited by
198
References
200
Citations by year
2026: 27 · 2025: 40 · 2024: 35 · 2023: 44 · 2022: 33 · 2021: 18
FWCI
2.85
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research Foundation (2020R1F1A1072795, 2018M3A9B5021319)
  • National Research Foundation of Korea (2020R1F1A1072795, 2018M3A9B5021319)
  • Ministry of Science and ICT, South Korea (2020R1F1A1072795)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Keywords
ocular drug delivery, retinal drug delivery, intravitreal injection, intravitreal implant, nanoparticles, hydrogels, port delivery system, anti-VEGF therapy, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular disease, subconjunctival administration, ocular bioavailability, minimally invasive drug delivery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. https://app.cochat.ai/papers/10.3390/pharmaceutics13010108
The paper
Kim, H. M., & Woo, S. J. (2021). Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13010108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.